Metastasis-free Survival — A New End Point in Prostate Cancer Trials
Volume: 378, Issue: 26, Pages: 2458 - 2460
Published: Jun 28, 2018
Abstract
The FDA’s approval of apalutamide for use in nonmetastatic castration-resistant prostate cancer (nmCRPC) was based on an improvement in metastasis-free survival. It was the first drug approval for nmCRPC and the first use of this primary end point to support drug...
Paper Details
Title
Metastasis-free Survival — A New End Point in Prostate Cancer Trials
Published Date
Jun 28, 2018
Volume
378
Issue
26
Pages
2458 - 2460
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History